BamSEC and AlphaSense Join Forces
Learn More

Orexigen Therapeutics, Inc.

Formerly OTC: OREXQ

Indentures Filter

EX-4.1
from 8-K 10 pages This Instrument of Resignation, Appointment and Acceptance (This “Instrument”), Dated as of March 20, 2018 (“Effective Date”), Is by and Among Orexigen Therapeutics, Inc. (The “Issuer”), Wilmington Savings Fund Society, Fsb, a Federal Savings Bank Duly Organized and Existing Under the Laws of the United States, as Successor Trustee (The “Successor Trustee”), and U.S. Bank National Association, a National Banking Association Duly Organized and Existing Under the Laws of the United States of America, as Resigning Trustee (The “Resigning Trustee”). Capitalized Terms Not Otherwise Defined Herein Shall Have the Same Meaning Ascribed to Such Terms in the Indenture (As Defined Below)
12/34/56
EX-4.1
from 8-K 100 pages Orexigen Therapeutics, Inc. as Issuer U.S. Bank National Association Indenture Dated as of February 23, 2017 2.75% Convertible Exchange Senior Notes Due 2020
12/34/56
EX-4.2
from 8-K 9 pages Second Supplemental Indenture
12/34/56
EX-4.1
from 8-K 100 pages Orexigen Therapeutics, Inc. as Issuer U.S. Bank National Association Indenture Dated as of February 23, 2017 2.75% Convertible Exchange Senior Notes Due 2020
12/34/56
EX-4.1
from 8-K 12 pages First Supplemental Indenture
12/34/56
EX-4.1
from 8-K 158 pages Orexigen Therapeutics, Inc. and U.S. Bank National Association, as Trustee and Collateral Agent Indenture Dated as of March 21, 2016 0% Convertible Senior Secured Notes Due 2020
12/34/56
EX-4.14
from S-3 19 pages Orexigen Therapeutics, Inc. and , as Warrant Agent Form of Debt Securities Warrant Agreement Dated as of Orexigen Therapeutics, Inc. Form of Debt Securities Warrant Agreement
12/34/56
EX-4.13
from S-3 22 pages Orexigen Therapeutics, Inc. and , as Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of Orexigen Therapeutics, Inc. Form of Preferred Stock Warrant Agreement Article 1 Issuance of Warrants and Execution and Delivery of Warrant Certificates
12/34/56
EX-4.12
from S-3 21 pages Orexigen Therapeutics, Inc. and , as Warrant Agent Form of Common Stock Warrant Agreement Dated as of Orexigen Therapeutics, Inc. Form of Common Stock Warrant Agreement Article 1 Issuance of Warrants and Execution and Delivery of Warrant Certificates
12/34/56
EX-4.10
from S-3 55 pages Orexigen Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 20 Debt Securities
12/34/56
EX-4.1
from 8-K 106 pages Orexigen Therapeutics, Inc. as Issuer 2.75% Convertible Senior Notes Due 2020 Indenture Dated as of December 6, 2013 Wilmington Trust, National Association as Trustee
12/34/56
EX-4.9
from S-3 2 pages Private and Confidential
12/34/56
EX-4.8
from S-3 49 pages Orexigen Therapeutics, Inc. Indenture Dated as of , 20 [Name of Trustee] Trustee
12/34/56
EX-4.1
from 8-K 13 pages Orexigen Therapeutics, Inc. Warrant to Purchase Common Stock
12/34/56
EX-4
from SC 13G/A 1 page Indenture or similar
12/34/56
EX-4.8
from S-3 56 pages Form of Indenture to Be Entered Into Between the Company and a Trustee to Be Named Orexigen Therapeutics, Inc. Indenture Dated as of , 20__ [Name of Trustee] Trustee
12/34/56
EX-4.8
from S-3 56 pages Form of Indenture to Be Entered Into Between the Company and a Trustee to Be Named Orexigen Therapeutics, Inc. Indenture Dated as of , 20__ [Name of Trustee] Trustee
12/34/56
EX-4.1
from 8-K 10 pages Orexigen Therapeutics, Inc. Registration Rights Waiver and Amendment January 6, 2008
12/34/56
EX-4.1
from S-1/A 3 pages Additional Abbreviations May Also Be Used Though Not in the Above List
12/34/56
EX-4.2
from S-1 36 pages Orexigen Therapeutics, Inc. Second Amended and Restated Investors’ Rights Agreement November 20, 2006
12/34/56